CN102648174B - 芳基化莰烯、它们的制备方法及其用途 - Google Patents

芳基化莰烯、它们的制备方法及其用途 Download PDF

Info

Publication number
CN102648174B
CN102648174B CN201080049552.1A CN201080049552A CN102648174B CN 102648174 B CN102648174 B CN 102648174B CN 201080049552 A CN201080049552 A CN 201080049552A CN 102648174 B CN102648174 B CN 102648174B
Authority
CN
China
Prior art keywords
hept
compound
dimethoxy
methyloct
dimethylbicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080049552.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN102648174A (zh
Inventor
R·梅克霍拉姆
L·马吉德
E·霍哈米
I·巴布
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43875675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102648174(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of CN102648174A publication Critical patent/CN102648174A/zh
Application granted granted Critical
Publication of CN102648174B publication Critical patent/CN102648174B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23—Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/215—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring having unsaturation outside the six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
    • C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
    • C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
    • C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
    • C07C45/70—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction with functional groups containing oxygen only in singly bound form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/09—Preparation of carboxylic acids or their salts, halides or anhydrides from carboxylic acid esters or lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757—Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
    • C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
CN201080049552.1A 2009-11-19 2010-11-18 芳基化莰烯、它们的制备方法及其用途 Expired - Fee Related CN102648174B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26267709P 2009-11-19 2009-11-19
US61/262,677 2009-11-19
PCT/IL2010/000970 WO2011061744A2 (en) 2009-11-19 2010-11-18 Novel arylated camphenes, processes for their preparation and uses thereof

Publications (2)

Publication Number Publication Date
CN102648174A CN102648174A (zh) 2012-08-22
CN102648174B true CN102648174B (zh) 2016-04-27

Family

ID=43875675

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080049552.1A Expired - Fee Related CN102648174B (zh) 2009-11-19 2010-11-18 芳基化莰烯、它们的制备方法及其用途

Country Status (25)

Country Link
US (2) US8722938B2 (enExample)
EP (1) EP2501669B1 (enExample)
JP (1) JP5960058B2 (enExample)
KR (1) KR20120091196A (enExample)
CN (1) CN102648174B (enExample)
AU (1) AU2010320467B2 (enExample)
BR (1) BR112012010518A2 (enExample)
CA (1) CA2774868C (enExample)
CL (1) CL2012001290A1 (enExample)
CO (1) CO6481008A2 (enExample)
CR (1) CR20120247A (enExample)
EC (1) ECSP12011864A (enExample)
ES (1) ES2665519T3 (enExample)
IL (1) IL218216A (enExample)
MA (1) MA33753B1 (enExample)
MX (2) MX2012005634A (enExample)
MY (1) MY184647A (enExample)
NZ (1) NZ599106A (enExample)
PE (1) PE20121187A1 (enExample)
PH (1) PH12012500897A1 (enExample)
RU (1) RU2578715C2 (enExample)
SG (2) SG10201407706VA (enExample)
UA (1) UA109414C2 (enExample)
WO (1) WO2011061744A2 (enExample)
ZA (1) ZA201200752B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2501669B1 (en) * 2009-11-19 2018-01-24 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Arylated camphenes, processes for their preparation and uses thereof
CA2956056A1 (en) 2014-10-27 2016-05-06 F. Hoffmann-La Roche Ag Radiolabeled cannabinoid receptor 2 ligand
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
US20180303793A1 (en) * 2015-10-16 2018-10-25 Scythian Biosciences Inc. Methods and compositions for treating traumatic brain injury
WO2018087767A1 (en) 2016-11-13 2018-05-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Process for the preparation of hu-910 and crystalline structure thereof
RU2651754C1 (ru) * 2016-11-25 2018-04-23 Федеральное государственное бюджетное учреждение науки Новосибирский институт органической химии им. Н.Н. Ворожцова Сибирского отделения Российской академии наук (НИОХ СО РАН) ПРИМЕНЕНИЕ АЛИФАТИЧЕСКИХ ИМИНОПРОИЗВОДНЫХ КАМФОРЫ В КАЧЕСТВЕ ЭФФЕКТИВНЫХ ИНГИБИТОРОВ РЕПРОДУКЦИИ ВИРУСА ГРИППА штамм A/California/07/09 (H1N1) pdm09 и A/Puerto Rico/8/34 (H1N1)
KR102063962B1 (ko) * 2017-10-25 2020-01-08 대구대학교 산학협력단 캄펜을 유효성분으로 함유하는 골다공증의 예방 또는 치료용 약학적 조성물
AU2019325479B2 (en) * 2018-08-20 2025-07-31 Bessor Pharma, Llc Novel cannabinoids and cannabinoid acids and their derivatives
EP4412974A1 (en) * 2021-10-10 2024-08-14 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Arylated fenchone derivatives, compositions comprising them, processes for their preparation and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2537647A (en) * 1948-02-21 1951-01-09 Firestone Tire & Rubber Co Rearrangement of terpenyl aryl ethers
WO2008154083A2 (en) * 2007-05-04 2008-12-18 Proteo Tech Inc. Compounds, compositions and methods for the treatment of synucleinopathies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE876241C (de) * 1943-04-07 1953-05-11 Lech Chemie Gersthofen Verfahren zur Herstellung von Riechstoffen aus Terpenphenolen
DE828394C (de) * 1948-10-02 1952-01-17 Chemische Werke Huels G M B H Verfahren zur Herstellung von UEberzuegen
US2647152A (en) * 1950-07-12 1953-07-28 Firestone Tire & Rubber Co Terpenylalkylphenols and their preparation
US3284359A (en) * 1963-12-26 1966-11-08 Gen Electric Barium potassium ferrite magnetic material exhibiting non-vanishing rotational hysteresis in applied magnetic fields
GB1306217A (enExample) * 1969-07-04 1973-02-07
US3800051A (en) * 1970-09-21 1974-03-26 Dow Chemical Co Reducing serum cholesterol with certain substituted phenols
GB1504862A (en) 1974-04-11 1978-03-22 Mar Pha Etu Expl Marques Terpeno-phenoxyalkylamines
US4112000A (en) * 1974-04-11 1978-09-05 Mar-Pha, Societe D'etude Et D'exploitation De Marques Terpenophenols
GB1548875A (en) * 1975-06-23 1979-07-18 Mar Pha Etu Expl Marques Terpnyl phen (oxy)elkyl amideines and their use in pharmaceutical compositions
US5648352A (en) 1991-09-13 1997-07-15 Merck & Co., Inc. Piperazinylcamphorsulfonyl oxytocin antagonists
HU227114B1 (en) 1999-05-11 2010-07-28 Egis Gyogyszergyar Nyilvanosan (1r, 2s, 4r)-(-)-2-[n,n-(dimethylamino-ethoxy)]-2-phenyl-1,7,7-trimethyl-bicyclo[2.2.1]heptane of high purity and pharmaceutically acceptable acid addition salts thereof, process for preparation of them and medicaments containing the same
UY26942A1 (es) 2000-09-20 2002-04-26 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
ATE340158T1 (de) 2000-11-08 2006-10-15 Syngenta Participations Ag Pyrrolcarboxamide und pyrrolcarbothioamide und deren agrochemische verwendungen
US8227643B2 (en) 2002-05-31 2012-07-24 Proteotech, Inc. Sirtuin 1 and the treatment of neurodegenerative diseases
SI2527315T1 (sl) 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
US8455687B2 (en) 2002-05-31 2013-06-04 Proteotech, Inc. Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies
US7601876B2 (en) 2002-05-31 2009-10-13 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis
RU2233262C1 (ru) * 2003-03-11 2004-07-27 Государственное учреждение Институт химии Коми научного центра Уральского отделения РАН Способ получения орто-терпенофенолов
CN1847207A (zh) * 2006-03-27 2006-10-18 上海应用技术学院 合成檀香的制备方法
EP2501669B1 (en) * 2009-11-19 2018-01-24 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Arylated camphenes, processes for their preparation and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2537647A (en) * 1948-02-21 1951-01-09 Firestone Tire & Rubber Co Rearrangement of terpenyl aryl ethers
WO2008154083A2 (en) * 2007-05-04 2008-12-18 Proteo Tech Inc. Compounds, compositions and methods for the treatment of synucleinopathies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Albrecht Berkessel, et al..Synthesis and Configurational Assignment of Chiral Salicylic Aldehydes: Novel Building Blocks for Asymmetric Catalysis.《European Journal of Organic Chemistry》.2002,(第16期),第2800-2807页. *
Bornyl- and Isobornyl-delta8-tetrahydrocannabinols: A Novel Class of Cannabinergic Ligands;Dai Lu, et al.;《Journal of Medicinal Chemistry》;20081001;第51卷(第20期);第6393-6399页 *
Synthesis and characterization of 2-substituted bornane pharmacophores for novel cannabinergic ligands;Richard I. Duclos Jr., et al.;《Tetrahedron Letters》;20080706;第49卷;第5587-5589页 *
Synthesis and Configurational Assignment of Chiral Salicylic Aldehydes: Novel Building Blocks for Asymmetric Catalysis;Albrecht Berkessel, et al.;《European Journal of Organic Chemistry》;20021231(第16期);第2800-2807页 *

Also Published As

Publication number Publication date
CR20120247A (es) 2012-06-12
MX2012005634A (es) 2012-09-07
CN102648174A (zh) 2012-08-22
BR112012010518A2 (pt) 2016-03-15
US8722938B2 (en) 2014-05-13
WO2011061744A2 (en) 2011-05-26
IL218216A0 (en) 2012-04-30
MX355972B (es) 2018-05-07
AU2010320467A1 (en) 2012-04-05
US20120245366A1 (en) 2012-09-27
ES2665519T3 (es) 2018-04-26
US9365534B2 (en) 2016-06-14
AU2010320467B2 (en) 2015-07-02
ECSP12011864A (es) 2012-07-31
IL218216A (en) 2015-05-31
UA109414C2 (uk) 2015-08-25
SG10201407706VA (en) 2015-02-27
CO6481008A2 (es) 2012-07-16
US20150038728A1 (en) 2015-02-05
NZ599106A (en) 2013-07-26
RU2578715C2 (ru) 2016-03-27
WO2011061744A3 (en) 2011-09-29
JP5960058B2 (ja) 2016-08-02
PH12012500897A1 (en) 2012-11-12
MA33753B1 (fr) 2012-11-01
MY184647A (en) 2021-04-13
CA2774868C (en) 2018-09-04
EP2501669A2 (en) 2012-09-26
RU2012106897A (ru) 2013-12-27
CL2012001290A1 (es) 2012-10-05
EP2501669B1 (en) 2018-01-24
PE20121187A1 (es) 2012-09-23
CA2774868A1 (en) 2011-05-26
ZA201200752B (en) 2014-06-25
KR20120091196A (ko) 2012-08-17
JP2013511511A (ja) 2013-04-04
SG179203A1 (en) 2012-04-27

Similar Documents

Publication Publication Date Title
CN102648174B (zh) 芳基化莰烯、它们的制备方法及其用途
US10221164B2 (en) Cannabinergic nitrate esters and related analogs
JP5059996B2 (ja) 新規インターロイキン−１および腫瘍壊死因子−αモジュレーター、前記モジュレーターの合成、ならびに前記モジュレーターの使用方法
JP4312594B2 (ja) 新規な二環式及び三環式カンナビノイド
US20040087590A1 (en) Novel biphenyl and biphenyl-like cannabinoids
JP2005508384A (ja) イミダゾール−４−カルボキシアミド誘導体、それらの製造及び肥満の処置のための使用
JP2005510492A (ja) 新規な種類の効力のあるカンナビミメティックリガンド
JPH0153671B2 (enExample)
KR910009936B1 (ko) 5-리폭시게나제 억제제로서의 치환된 인돌, 벤조푸란 및 벤조티오펜 유도체
Huang et al. Design and synthesis of novel diosgenin-triazole hybrids targeting inflammation as potential neuroprotective agents
JPH09301915A (ja) フラボン及びナフタレン誘導体
CA2438509C (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
WO2014180327A1 (zh) 苯酚衍生物及其制备方法和在医药上的应用
HK1169095A (en) Novel arylated camphenes, processes for their preparation and uses thereof
WO2014063587A1 (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
IL237753A (en) Aryl-backed campaigns, processes for their preparation and use
KR101783199B1 (ko) 피스아타놀 유도체 합성방법 및 피스아타놀 유도체를 포함하는 항염증 약학 조성물
JPH03163042A (ja) カルコン誘導体
JP2011506597A (ja) 置換３−ヒドロキシピリジン及びその医薬組成物
JP2007262022A (ja) 新規２−チオフェンカルボキサミド誘導体
US3882239A (en) Method of treating pain fever and inflammation and composition
TW201930309A (zh) Ask1抑制劑化合物及其用途
JPH10512553A (ja) 新規な化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1169095

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20160427

Termination date: 20201118

CF01 Termination of patent right due to non-payment of annual fee